Zacks Research Issues Pessimistic Estimate for DYAI Earnings

Dyadic International Inc. (NASDAQ:DYAI) – Investment analysts at Zacks Research dropped their FY2026 earnings estimates for Dyadic International in a report released on Monday, March 30th. Zacks Research analyst J. Vandermosten now forecasts that the biotechnology company will post earnings of ($0.12) per share for the year, down from their prior forecast of ($0.11). The consensus estimate for Dyadic International’s current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Dyadic International’s FY2027 earnings at ($0.16) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Up 4.4%

DYAI stock opened at $0.89 on Wednesday. The company has a 50 day moving average price of $0.82 and a two-hundred day moving average price of $0.94. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.68 and a current ratio of 2.68. The stock has a market capitalization of $32.43 million, a P/E ratio of -3.56 and a beta of 1.21. Dyadic International has a one year low of $0.65 and a one year high of $1.43.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). Dyadic International had a negative net margin of 239.67% and a negative return on equity of 695.96%. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.34 million.

Institutional Investors Weigh In On Dyadic International

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Marathon Capital Management acquired a new position in shares of Dyadic International in the 3rd quarter valued at $41,000. Geode Capital Management LLC boosted its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the last quarter. Chapin Davis Inc. grew its stake in shares of Dyadic International by 5.6% during the 3rd quarter. Chapin Davis Inc. now owns 932,004 shares of the biotechnology company’s stock valued at $1,100,000 after buying an additional 49,155 shares during the period. Finally, Truist Financial Corp grew its stake in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares during the period. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.